New class of orthopoxvirus antiviral drugs that block viral maturation

scientific article

New class of orthopoxvirus antiviral drugs that block viral maturation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.78.22.12147-12156.2004
P932PMC publication ID525040
P698PubMed publication ID15507601
P5875ResearchGate publication ID8208803

P50authorDennis E. HrubyQ113288408
P2093author name stringChelsea M Byrd
Robert Rothlein
Robert C Andrews
Adnan M Mjalli
Mohan Rao
Tové C Bolken
Katrina L Owens
Murty N Arimilli
Tariq Andrea
P2860cites workA low-viscosity epoxy resin embedding medium for electron microscopyQ26778471
A new protease required for cell-cycle progression in yeastQ27938681
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusQ29614207
Vaccinia Virus Replication I. Requirement for the Host-Cell NucleusQ30850654
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovirQ33545117
Cidofovir in the treatment of poxvirus infectionsQ34134474
In vitro activity of potential anti-poxvirus agentsQ35077243
Smallpox vaccination: a review, part II. Adverse eventsQ35175732
Encephalitis complicating smallpox vaccinationQ35182272
Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion componentQ36645421
The vaccinia virus I7L gene product is the core protein proteinaseQ39686660
Molecular Dissection of the Vaccinia Virus I7L Core Protein ProteinaseQ39997670
African swine fever virus protease, a new viral member of the SUMO-1-specific protease familyQ40613575
Sensitivity of herpes simplex virus, vaccinia virus, and adenoviruses to deoxyribonucleic acid inhibitors and thiosemicarbazones in a plaque suppression testQ41019711
A SIMPLIFIED LEAD CITRATE STAIN FOR USE IN ELECTRON MICROSCOPY.Q41066255
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitisQ41372087
Rifampicin: a specific inhibitor of vaccinia virus assemblyQ43498675
Selective inhibition of vaccinia virus by the antibiotic rifampicinQ44293072
Relation of poly(adenosine diphosphoribose) synthesis to DNA synthesis and cell growthQ44438710
Immunolocalization of vaccinia virus structural proteins during virion formationQ45776741
Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virusQ45795296
Specific inhibition of vaccinia virus growth by 2'-O-methyladenosine: isolation of a drug-resistant virus mutantQ45795835
The effect of hydroxyurea on virus development. II. Vaccinia virusQ45812224
An abbreviated method of the double lead stain techniqueQ68958412
Selection of recombinant vaccinia viruses on the basis of plaque formationQ71866680
P433issue22
P304page(s)12147-12156
P577publication date2004-11-01
P1433published inJournal of VirologyQ1251128
P1476titleNew class of orthopoxvirus antiviral drugs that block viral maturation
P478volume78

Reverse relations

cites work (P2860)
Q346760275-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity
Q36505563A novel inhibitor of dengue virus replication that targets the capsid protein
Q34421628Activity, specificity, and probe design for the smallpox virus protease K7L
Q35039792Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains
Q35784850Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors
Q27652695Crystal structure of poxvirus thymidylate kinase: An unexpected dimerization has implications for antiviral therapy
Q24811081Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity
Q33303858Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches
Q38617932Historical perspectives in the development of antiviral agents against poxviruses
Q33302240Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly
Q42143723Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide
Q33234918Mutational analysis of the potential catalytic residues of the VV G1L metalloproteinase
Q34583461Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase
Q36074391Orthopoxvirus targets for the development of antiviral therapies
Q37173398Orthopoxvirus targets for the development of new antiviral agents.
Q42122542Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication
Q42974816Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system
Q35759004Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase
Q34698954Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues
Q38089868The design and development of drugs acting against the smallpox virus.
Q34984243Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure
Q40195477Vaccinia virus G1 protein: absence of autocatalytic self-processing.
Q36482612Vaccinia virus proteolysis--a review